EX-99.3 4 pacb-20141023ex993a3ec47.htm EX-99.3 Q3FY2014 PR 8-K Filed Exhibit 99.3

 

Exhibit 99.3

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine-Month Periods Ended September 30,

(in thousands)

2014

 

2013

Cash flows from operating activities

 

 

 

 

 

Net loss

$

(47,185)

 

$

(62,062)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

Depreciation

 

3,311 

 

 

4,238 

Amortization of debt discount and financing costs

 

579 

 

 

418 

Stock-based compensation

 

6,944 

 

 

7,361 

Other

 

242 

 

 

(73)

Changes in assets and liabilities

 

 

 

 

 

Accounts receivable

 

376 

 

 

(992)

Inventory

 

(1,348)

 

 

171 

Prepaid expenses and other assets

 

85 

 

 

791 

Accounts payable

 

4,128 

 

 

425 

Accrued expenses

 

821 

 

 

544 

Deferred service revenue

 

1,661 

 

 

56 

Deferred contractual revenue

 

(5,088)

 

 

35,000 

Other liabilities

 

(637)

 

 

(1,136)

Net cash used in operating activities

 

(36,111)

 

 

(15,259)

Cash flows from investing activities

 

 

 

 

 

Purchase of property and equipment

 

(1,132)

 

 

(807)

Purchase of investments

 

(97,468)

 

 

(141,549)

Maturities of investments

 

119,673 

 

 

133,391 

Net cash provided by (used in) investing activities

 

21,073 

 

 

(8,965)

Cash flows from financing activities

 

 

 

 

 

Proceeds from issuance of common stock from equity plans

 

3,319 

 

 

2,731 

Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs

 

20,768 

 

 

19,954 

Proceeds from issuance of Facility Agreement, net of issuance costs

 

 —

 

 

19,766 

Net cash provided by financing activities

 

24,087 

 

 

42,451 

Net increase in cash and cash equivalents

 

9,049 

 

 

18,227 

Cash and cash equivalents at beginning of period

 

26,362 

 

 

46,540 

Cash and cash equivalents at end of period

$

35,411 

 

$

64,767